Page URL: https://www.bionews.org.uk/page_92129

deCODE is back

25 January 2010
Appeared in BioNews 542

The pioneering genetics research company, deCODE, re-emerged last week as a private company with new financial backing. Based in Reykjavik, Iceland, the original company deCODE Genetics, Inc led the way internationally in genetic testing and diagnostics for over a decade. With unique access to genetic information from Iceland's isolated population, the biotech firm has made important discoveries, such as identifying gene variants associated with common conditions such as schizophrenia, cancer and heart disease. However, deCODE's scientific success failed to translate into profits and, after 13 years of financial troubles, including major losses following the fall of Lehman Brothers in 2008, the company filed for bankruptcy in November 2009.

Last week, however, a Delaware (US) bankruptcy court approved the sale deCODE's subsidiary, Islensk Erfdagreining, to Saga Investments LLC, thereby salvaging some of deCODE's core business under a new management and a new name: deCODE efh. Saga is a consortium that includes leading life science investors Polaris Ventures and ARCH Venture Partners, and investors who invested in the orginal deCODE.

The 'New deCODE', as it is referred to, will continue to carry out its deCODE diagnostics disease risk tests, deCODEme(TM) personal genome scans, and contract service offerings such as genotyping, sequencing and data analysis. It is the high quality of deCODE's scientific work that saved it: 'From an investor's perspective, it was the power of the content being created', says Terrance McGuire, general partner at Polaris.

deCODE efh is to be led by a expert two-man team: Earl Collier, previously Vice President of Genzyme Corp, has been appointed CEO, and Kari Stefansson, neuroscientist and founder of deCODE Inc., has been appointed Executive Chairman and President of Research. 'New deCODE' hopes to continue to lead the way in genetic research and its application. Henceforth, rather than working on creating drugs in house, deCODE will partner drug companies to develop products that interpret their research into medical therapies.

Meanwhile, original parent company deCODE Genetics, Inc has changed its name to DGI Resolution, Inc; it expects to be liquidated in accordance with procedures currently undergoing at the bankruptcy court.

SOURCES & REFERENCES
Announcing the New deCODE
PR Newswire |  21 January 2010
deCODE genetics, Inc. Announces Sale of Its Icelandic Human Genetics Unit deCODE genetics ehf
PR Newswire |  21 January 2010
deCODE Genetics Rises From the Ashes
ScienceInsider |  21 January 2010
deCODE reborn
The Scientist |  21 January 2010
Exiting Bankruptcy, DeCode Lands in V.C. Hands
The New York Times |  22 January 2010
Gene pioneer deCODE resurrected
Financial Times |  21 January 2010
Icelandic gene pioneer Decode back as private firm
Reuters |  21 January 2010
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
30 March 2015 - by Dr Meghna Kataria 
Scientists in Iceland have produced a comprehensive portrait of the nation's genetic makeup...
15 December 2014 - by Dr Jess Buxton 
This discussion around the role of commerce in genetics and fertility treatment coincided with the launch of 23andMe's controversial personal genome service in the UK. Issues around health interventions following personal genetic testing were the focus of the second session at PET's conference, which asked: 'Whose genes are they anyway?'...
17 December 2012 - by Holly Rogers 
The US biotechnology company Amgen will buy deCODE Genetics, which provides products and services for genome analysis, for $415 million...
1 February 2010 - by Dr Nadeem Shaikh 
A company in the US is offering potential parents the chance to test whether their future offspring might develop serious health problems by selling them home genetic test kits. Counsyl allows customers to send a saliva sample via the post, which is used in conjunction with DNA chip technology to screen if the person is a carrier for a single genetic mutation known to cause a disease. If both parents carry the same mutation,...
30 November 2009 - by Dr Jay Stone 
Dr Kari Stefansson, founder of biopharmaceutical company deCODE genetics, has claimed that the company will be able to continue normal services despite announcing bankruptcy last week....
22 November 2009 - by Dr Jay Stone 
The commercialisation of 'personalised' genetic medicine was delivered a blow last week as the Icelandic biopharmaceutical company deCODE genetics was forced to file for bankruptcy. The company was reported to be restructuring but are now considering an offer from Saga investment for their drug development branch and have been forced to put their other assets up for sale also....
14 April 2009 - by MacKenna Roberts 
The impending financial demise of leading human genetics biotechnology company deCODE Genetics is seen as a direct blow to genetic medicine and ultimately signalling wider ramifications for the impact of the global financial crisis on the genomics industry as a whole. Chief executive Kari Stefansson announced, on...
14 February 2000 - by BioNews 
deCODE genetics, the controversial Icelandic genetics research firm headed by Kari Stefansson, is to be floated on the stock market. It is likely to become one of the largest biotech firms in Europe. 'deCODE is going to go like a bomb. It would not surprise me to see its value...
22 March 1999 - by BioNews 
The on-going debate surrounding the Icelandic gene database project is thoroughly explored in the Sunday Times. Explaining the significant ramifications of a genetically isolated community such as Iceland for research into the causes of genetically inherited diseases, the article covers the setting up of Iceland's first biotechnology firm, Decode Genetics...
HAVE YOUR SAY
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.